{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:54:24Z","timestamp":1790830464926,"version":"4.1.0"},"reference-count":229,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001595","name":"Dystonia Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jns.2018.09.022","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T03:36:31Z","timestamp":1538019391000},"page":"52-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Huntington disease: A quarter century of progress since the gene discovery"],"prefix":"10.1016","volume":"396","author":[{"given":"Claudia M.","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5940","key":"10.1016\/j.jns.2018.09.022_bb0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington's disease","volume":"306","author":"Gusella","year":"1983","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell."},{"issue":"Pt 8","key":"10.1016\/j.jns.2018.09.022_bb0015","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/brain\/aww165","article-title":"George Huntington: a legacy of inquiry empathy and hope","volume":"139","author":"Wexler","year":"2016","journal-title":"Brain."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrg2748","article-title":"Repeat expansion disease: progress and puzzles in disease pathogenesis","volume":"11","author":"La Spada","year":"2010","journal-title":"Nat. Rev. Genetics."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb0025","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb0030","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","article-title":"CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion","volume":"78","author":"Lee","year":"2012","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0035","doi-asserted-by":"crossref","DOI":"10.2217\/nmt.13.18","article-title":"Managing juvenile Huntington's disease","volume":"3","author":"Quarrell","year":"2013","journal-title":"Neurodegener Dis Manag."},{"issue":"7","key":"10.1016\/j.jns.2018.09.022_bb0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.parkreldis.2014.03.017","article-title":"Late-onset Huntington's disease: diagnostic and prognostic considerations","volume":"20","author":"Koutsis","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.jns.2018.09.022_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0050","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron."},{"key":"10.1016\/j.jns.2018.09.022_bb0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/bs.ctdb.2016.07.006","article-title":"Neurotoxicity pathways in Drosophila models of the Polyglutamine disorders","volume":"121","author":"Krench","year":"2017","journal-title":"Curr Top Dev Biol."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbrc.2016.07.058","article-title":"Striatal synaptic dysfunction and altered calcium regulation in Huntington disease","volume":"483","author":"Raymond","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0065","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1007\/s12035-017-0477-7","article-title":"Huntington disease as a neurodevelopmental disorder and early signs of the disease in stem cells","volume":"55","author":"Wiatr","year":"2018","journal-title":"Mol Neurobiol."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin Genet."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0075","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","article-title":"Genetic modifiers of Huntington's disease","volume":"29","author":"Gusella","year":"2014","journal-title":"Mov Disord."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0080","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archneur.1997.00550210019008","article-title":"Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset","volume":"54","author":"Jason","year":"1997","journal-title":"Arch Neurol."},{"issue":"19","key":"10.1016\/j.jns.2018.09.022_bb0085","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","article-title":"Weight loss in Huntington disease increases with higher CAG repeat number","volume":"71","author":"Aziz","year":"2008","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ejhg.2010.229","article-title":"HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia","volume":"19","author":"Warby","year":"2011","journal-title":"Eur J Hum Genet."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0095","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington's disease","volume":"162","author":"Genetic Modifiers of Huntington's Disease","year":"2015","journal-title":"Cell."},{"issue":"19","key":"10.1016\/j.jns.2018.09.022_bb0100","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/hmg\/ddx286","article-title":"A modifier of Huntington's disease onset at the MLH1 locus","volume":"26","author":"Lee","year":"2017","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0105","first-page":"593","article-title":"Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease","volume":"57","author":"Ranen","year":"1995","journal-title":"Am J Hum Genet."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jmg.2007.050930","article-title":"Factors associated with HD CAG repeat instability in Huntington disease","volume":"44","author":"Wheeler","year":"2007","journal-title":"J Med Genet."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/jmedgenet-2013-101796","article-title":"CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease","volume":"50","author":"Semaka","year":"2013","journal-title":"J Med Genet."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb0120","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/hmg\/3.12.2103","article-title":"DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence","volume":"3","author":"Squitieri","year":"1994","journal-title":"Hum Mol Genet."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0125","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin haplotypes provide prioritized target panels for Allele-specific silencing in Huntington disease patients of European Ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Mol Ther."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/WNL.0000000000002858","article-title":"Huntington disease reduced penetrance alleles occur at high frequency in the general population","volume":"87","author":"Kay","year":"2016","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12035-015-9662-8","article-title":"Huntington's disease: Relationship between phenotype and genotype","volume":"54","author":"Sun","year":"2017","journal-title":"Mol Neurobiol."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/mds.21195","article-title":"Autopsy-proven Huntington's disease with 29 trinucleotide repeats","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0145","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/mds.23623","article-title":"Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene","volume":"26","author":"Squitieri","year":"2011","journal-title":"Mov Disord."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/WNL.0000000000002944","article-title":"Clinical manifestations of intermediate allele carriers in Huntington disease","volume":"87","author":"Cubo","year":"2016","journal-title":"Neurology."},{"issue":"22","key":"10.1016\/j.jns.2018.09.022_bb0155","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1212\/WNL.0b013e318294b304","article-title":"Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS","volume":"80","author":"Killoran","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2018.09.022_bb0160","series-title":"Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT: Tremor and Other Hyperkinetic Movements","first-page":"2","author":"Ha","year":"2012"},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3233\/JHD-140120","article-title":"Is there convincing evidence that intermediate repeats in the HTT gene cause Huntington's Disease?","volume":"4","author":"Oosterloo","year":"2015","journal-title":"J Huntingtons Dis."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmg.2014.11.005","article-title":"A new mutation for Huntington disease following maternal transmission of an intermediate allele","volume":"58","author":"Semaka","year":"2015","journal-title":"Eur J Med Genet."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0175","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1073\/pnas.0800048105","article-title":"DNA instability in postmitotic neurons","volume":"105","author":"Gonitel","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"16","key":"10.1016\/j.jns.2018.09.022_bb0180","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","article-title":"Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset","volume":"18","author":"Swami","year":"2009","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/nan.12465","article-title":"Review: Somatic mutations in neurodegeneration","volume":"44","author":"Leija-Salazar","year":"2018","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajmg.b.32618","article-title":"The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population","volume":"177","author":"Kay","year":"2018","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.parkreldis.2014.10.025","article-title":"Epidemiology of Huntington's disease in Finland","volume":"21","author":"Sipila","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0200","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord."},{"key":"10.1016\/j.jns.2018.09.022_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-801893-4.00003-1","article-title":"Epidemiology of Huntington disease","volume":"144","author":"Kay","year":"2017","journal-title":"Handb Clin Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup","volume":"84","author":"Warby","year":"2009","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.jns.2018.09.022_bb0215","first-page":"141","article-title":"Uber die Beteiligung der grossen basalen Gehirnganglien bei Bewegungsstorungen und insbesondere bei Chorea","volume":"14","author":"Anton","year":"1896","journal-title":"Jahrbucher Psychiat Neurol (Lpz)."},{"key":"10.1016\/j.jns.2018.09.022_bb0220","first-page":"333","article-title":"Deux cas de chor\u00e9e hereditaire avec autopsies","volume":"4","author":"Lanois","year":"1987","journal-title":"Arch Neurol (Paris)."},{"key":"10.1016\/j.jns.2018.09.022_bb0225","first-page":"891","article-title":"Uber die anatomische Grundlage der Huntingtonischen Chorea und der choreatischen Bewegungen uberhaupt","volume":"30","author":"Alzheimer","year":"1911","journal-title":"Neurol Cbl."},{"issue":"16","key":"10.1016\/j.jns.2018.09.022_bb0230","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/WNL.0b013e31826e9a5d","article-title":"Assessment of cortical and striatal involvement in 523 Huntington disease brains","volume":"79","author":"Hadzi","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2018.09.022_bb0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-801893-4.00020-1","article-title":"Structural imaging in premanifest and manifest Huntington disease","volume":"144","author":"Scahill","year":"2017","journal-title":"Handb Clin Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/brain.2017.0538","article-title":"Whole-brain connectivity in a large study of Huntington's disease gene mutation carriers and healthy controls","volume":"8","author":"Espinoza","year":"2018","journal-title":"Brain Connect."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0245","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain","volume":"26","author":"Rub","year":"2016","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0166-2236(95)80020-3","article-title":"The functional anatomy of disorders of the basal ganglia","volume":"18","author":"Albin","year":"1995","journal-title":"Trends Neurosci."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0255","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hbm.22055","article-title":"The structural correlates of functional deficits in early huntington's disease","volume":"34","author":"Delmaire","year":"2013","journal-title":"Hum Brain Mapp."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0260","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/mds.23762","article-title":"A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study","volume":"26","author":"Rosas","year":"2011","journal-title":"Mov Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0265","article-title":"Regional atrophy associated with cognitive and motor function in prodromal Huntington disease","volume":"2","author":"Aylward","year":"2013","journal-title":"J Huntingtons Dis."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0270","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-010-0742-6","article-title":"Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses","volume":"120","author":"Gabery","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0275","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jne.12190","article-title":"Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models","volume":"26","author":"van Wamelen","year":"2014","journal-title":"J Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1750-3639.2012.00629.x","article-title":"Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process","volume":"23","author":"Rub","year":"2013","journal-title":"Brain Pathol."},{"issue":"5-6","key":"10.1016\/j.jns.2018.09.022_bb0285","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s12311-017-0865-6","article-title":"Cerebellar gray matter alterations in Huntington disease: A voxel-based morphometry study","volume":"16","author":"de Azevedo","year":"2017","journal-title":"Cerebellum."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0290","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.jns.2018.09.022_bb0295","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/brain\/awq280","article-title":"Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment","volume":"134","author":"Nopoulos","year":"2011","journal-title":"Brain."},{"issue":"15","key":"10.1016\/j.jns.2018.09.022_bb0300","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/WNL.0b013e3181d8c20a","article-title":"Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study","volume":"74","author":"Stoffers","year":"2010","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0305","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","article-title":"Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study","volume":"32","author":"Politis","year":"2011","journal-title":"Hum Brain Mapp."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0310","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.25171","article-title":"Predicting clinical diagnosis in Huntington's disease: An imaging polymarker","volume":"83","author":"Mason","year":"2018","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.870100116","article-title":"Tourettism associated with Huntington's disease","volume":"10","author":"Jankovic","year":"1995","journal-title":"Mov Disord."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0320","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1590\/0004-282X20150192","article-title":"Juvenile Huntington disease in Argentina","volume":"74","author":"Gatto","year":"2016","journal-title":"Arq Neuropsiquiatr."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0325","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/mds.25864","article-title":"The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation","volume":"29","author":"Papoutsi","year":"2014","journal-title":"Mov Disord."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb0330","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2018.09.022_bb0335","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease","volume":"25","author":"Martinez-Horta","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.jns.2018.09.022_bb0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneumeth.2015.12.007","article-title":"Cognitive assessment strategies in Huntington's disease research","volume":"265","author":"Stout","year":"2016","journal-title":"J Neurosci Methods."},{"key":"10.1016\/j.jns.2018.09.022_bb0345","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnagi.2013.00012","article-title":"Refining the diagnosis of Huntington disease: the PREDICT-HD study","volume":"5","author":"Biglan","year":"2013","journal-title":"Front Aging Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0350","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaneurol.2015.2736","article-title":"linical-genetic associations in the prospective Huntington at risk observational study (PHAROS): Implications for clinical trials","volume":"73","author":"Huntington Study Group Pharos Investigators","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1-2","key":"10.1016\/j.jns.2018.09.022_bb0355","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jns.2008.09.029","article-title":"Late onset Huntington Disease: clinical and genetic characteristics of 34 cases","volume":"276","author":"Lipe","year":"2009","journal-title":"J Neurol Sci."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0360","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/(SICI)1096-8628(19961218)66:3<281::AID-AJMG9>3.0.CO;2-S","article-title":"Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease","volume":"66","author":"Alford","year":"1996","journal-title":"Am J Med Genet."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0365","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JHD-140111","article-title":"The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects","volume":"3","author":"Davis","year":"2014","journal-title":"J Huntingtons Dis."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0370","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11910-014-0514-0","article-title":"Diagnosis and treatment of chorea syndromes","volume":"15","author":"Hermann","year":"2015","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ane.12609","article-title":"Hereditary chorea - what else to consider when the Huntington's disease genetics test is negative?","volume":"135","author":"Malek","year":"2017","journal-title":"Acta Neurol Scand."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0380","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/mds.22925","article-title":"Psychogenic chorea associated with family history of Huntington disease","volume":"25","author":"Fekete","year":"2010","journal-title":"Mov Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0385","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mds.26527","article-title":"Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force","volume":"31","author":"Marras","year":"2016","journal-title":"Mov Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0390","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/WCO.0000000000000352","article-title":"Recent advances in genetics of chorea","volume":"29","author":"Mencacci","year":"2016","journal-title":"Curr Opin Neurol."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0395","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2016.2215","article-title":"Expanding the spectrum of genes involved in Huntington disease using a combined clinical and genetic approach","volume":"73","author":"Mariani","year":"2016","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0400","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.0000000000000061","article-title":"C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies","volume":"82","author":"Hensman Moss","year":"2014","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0405","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neurobiolaging.2014.08.020","article-title":"C9ORF72 hexanucleotide repeat expansions are a frequent cause of Huntington disease phenocopies in the Greek population","volume":"36","author":"Koutsis","year":"2015","journal-title":"Neurobiol Aging."},{"key":"10.1016\/j.jns.2018.09.022_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/4f8606b742ef3","article-title":"The prevalence of Juvenile Huntington's disease: A review of the literature and meta-analysis","volume":"4","author":"Quarrell","year":"2012","journal-title":"PLoS Curr."},{"issue":"14","key":"10.1016\/j.jns.2018.09.022_bb0415","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/mds.25237","article-title":"Seizures in juvenile Huntington's disease: Frequency and characterization in a multicenter cohort","volume":"27","author":"Cloud","year":"2012","journal-title":"Mov Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0420","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/nmt-2017-0019","article-title":"A survey-based study identifies common but unrecognized symptoms in a large series of juvenile Huntington's disease","volume":"7","author":"Moser","year":"2017","journal-title":"Neurodegener Dis Manag."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0425","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/mds.26011","article-title":"Diagnostic criteria for Huntington's disease based on natural history","volume":"29","author":"Reilmann","year":"2014","journal-title":"Mov Disord."},{"issue":"7","key":"10.1016\/j.jns.2018.09.022_bb0430","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/archneur.57.7.1040","article-title":"Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene","volume":"57","author":"Kirkwood","year":"2000","journal-title":"Arch Neurol."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb0435","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1212\/WNL.36.10.1279","article-title":"The diagnosis of Huntington's disease","volume":"36","author":"Folstein","year":"1986","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0440","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mds.870050202","article-title":"Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals","volume":"5","author":"Penney","year":"1990","journal-title":"Mov Disord."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0445","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-011-6172-0","article-title":"Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease","volume":"259","author":"Rupp","year":"2012","journal-title":"J Neurol."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0450","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/s00415-010-5632-2","article-title":"Huntington's disease: changes in saccades and hand-tapping over 3 years","volume":"257","author":"Antoniades","year":"2010","journal-title":"J Neurol."},{"issue":"1-2","key":"10.1016\/j.jns.2018.09.022_bb0455","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2011.09.035","article-title":"Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression","volume":"313","author":"Patel","year":"2012","journal-title":"J Neurol Sci."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0460","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.57.4.658","article-title":"Clinical markers of early disease in persons near onset of Huntington's disease","volume":"57","author":"Paulsen","year":"2001","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0465","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1037\/a0029218","article-title":"PREDICT-HD Investigators of the Huntington Study Group. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease","volume":"26","author":"Smith","year":"2012","journal-title":"Neuropsychology."},{"issue":"2-3","key":"10.1016\/j.jns.2018.09.022_bb0470","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.psychres.2011.09.005","article-title":"Patterns of serotonergic antidepressant usage in prodromal Huntington disease","volume":"196","author":"Rowe","year":"2012","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0475","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in Huntington disease: diagnosis and treatment","volume":"11","author":"Paulsen","year":"2011","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0480","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0b013e3181eccfa2","article-title":"Mild cognitive impairment in prediagnosed Huntington disease","volume":"75","author":"Duff","year":"2010","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0485","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp-2011-301732","article-title":"PREDICT-HD Investigators of the Huntington Study Group. Cognitive domains that predict time to diagnosis in prodromal Huntington disease","volume":"83","author":"Harrington","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","article-title":"Neurocognitive signs in prodromal Huntington disease","volume":"25","author":"Stout","year":"2011","journal-title":"Neuropsychology."},{"key":"10.1016\/j.jns.2018.09.022_bb0495","series-title":"Huntington Disease: The Complexities of Making and Disclosing a Clinical Diagnosis After Premanifest Genetic Testing, Tremor and Other Hyperkinetic Movements","first-page":"467","volume":"7","author":"McCusker","year":"2017"},{"key":"10.1016\/j.jns.2018.09.022_bb0500","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-801893-4.00010-9","article-title":"Genetic testing for Huntington disease","volume":"144","author":"Quaid","year":"2017","journal-title":"Handb Clin Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-0004.2010.01538.x","article-title":"Uptake of Huntington disease predictive testing in a complete population","volume":"80","author":"Morrison","year":"2011","journal-title":"Clin Genet."},{"issue":"2-3","key":"10.1016\/j.jns.2018.09.022_bb0510","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.brainresbull.2006.10.023","article-title":"Predictive testing for Huntington's disease","volume":"72","author":"Tibben","year":"2007","journal-title":"Brain Res Bull."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0515","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/01.WNL.0000032255.75650.C2","article-title":"French group for presymptomatic testing in neurogenetic disorders. Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias","volume":"59","author":"Goizet","year":"2002","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0520","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10897-017-0085-8","article-title":"Prospective evaluation of predictive DNA testing for Huntington's disease in a large German center","volume":"26","author":"Ibisler","year":"2017","journal-title":"J Genet Couns."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0525","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymgme.2010.12.001","article-title":"Experience over fifteen years with a protocol for predictive testing for Huntington disease","volume":"102","author":"Dufrasne","year":"2011","journal-title":"Mol Genet Metab."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0530","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/302374","article-title":"A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease","volume":"64","author":"Almqvist","year":"1999","journal-title":"Am J Hum Genet."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0535","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.psc.2015.01.008","article-title":"Genetic testing and counseling in the diagnosis and management of young-onset dementias","volume":"38","author":"Goldman","year":"2015","journal-title":"Psychiatr Clin North Am."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0540","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1037\/0278-6133.23.2.189","article-title":"Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test","volume":"23","author":"Timman","year":"2004","journal-title":"Health Psychol."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0545","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1037\/0278-6133.16.1.36","article-title":"Predictors of psychological adjustment to genetic testing for Huntington's disease","volume":"16","author":"Codori","year":"1997","journal-title":"Health Psychol."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0550","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/gte.2004.8.114","article-title":"Prevalence of major depression one year after predictive testing for Huntington's disease","volume":"8","author":"Codori","year":"2004","journal-title":"Genet Test."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0555","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10897-010-9329-6","article-title":"More appreciation of life or regretting the test? Experiences of living as a mutation carrier of Huntington's disease","volume":"20","author":"Hagberg","year":"2011","journal-title":"J Genet Couns."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0560","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mds.24024","article-title":"Age, CAG repeat length, and clinical progression in Huntington's disease","volume":"27","author":"Rosenblatt","year":"2012","journal-title":"Mov Disord."},{"issue":"Pt 2","key":"10.1016\/j.jns.2018.09.022_bb0565","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/brain\/111.2.223","article-title":"The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement","volume":"111","author":"Thompson","year":"1988","journal-title":"Brain."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0570","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.22953","article-title":"Cognitive and functional decline in Huntington's disease: dementia criteria revisited","volume":"25","author":"Peavy","year":"2010","journal-title":"Mov Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0575","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/arclin\/acq038","article-title":"Episodic memory in dementia: Characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases","volume":"25","author":"Aretouli","year":"2010","journal-title":"Arch Clin Neuropsychol."},{"key":"10.1016\/j.jns.2018.09.022_bb0580","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0585","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","article-title":"Classifying neurocognitive disorders: the DSM-5 approach","volume":"10","author":"Sachdev","year":"2014","journal-title":"Nat Rev Neurol."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0590","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/mds.25422","article-title":"Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease","volume":"28","author":"Hart","year":"2013","journal-title":"Mov Disord."},{"key":"10.1016\/j.jns.2018.09.022_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1288","article-title":"Seven-year clinical follow-up of premanifest carriers of Huntington's disease","volume":"3","author":"Hart","year":"2011","journal-title":"PLoS Curr."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0600","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/mds.25388","article-title":"Selective executive dysfunction but intact risky decision-making in early Huntington's disease","volume":"28","author":"Holl","year":"2013","journal-title":"Mov Disord."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb0605","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0610","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jad.2011.10.031","article-title":"Suicidality in Huntington's disease","volume":"136","author":"Hubers","year":"2012","journal-title":"J Affect Disord."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0615","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.psychres.2011.05.006","article-title":"Suicidal ideation in Huntington disease: the role of comorbidity","volume":"188","author":"Wetzel","year":"2011","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0620","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JHD-160206","article-title":"Risk factors for suicidal ideation in people at risk for Huntington's disease","volume":"5","author":"Anderson","year":"2016","journal-title":"J Huntingtons Dis."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0625","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1176\/appi.ajp.162.4.725","article-title":"Critical periods of suicide risk in Huntington's disease","volume":"162","author":"Paulsen","year":"2005","journal-title":"Am J Psychiatry."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0630","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/jnnp.2009.171926","article-title":"Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease","volume":"81","author":"Orth","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0635","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.biopsych.2006.04.034","article-title":"Probability of obsessive and compulsive symptoms in Huntington's disease","volume":"61","author":"Beglinger","year":"2007","journal-title":"Biol Psychiatry."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0640","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1176\/jnp.23.4.jnp399","article-title":"Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease","volume":"23","author":"Rickards","year":"2011","journal-title":"J Neuropsych Clin Neurosci"},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0645","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mds.22412","article-title":"Health-related quality of life in Huntington's disease: Which factors matter most?","volume":"24","author":"Ho","year":"2009","journal-title":"Mov Disord."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0650","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00702-012-0787-x","article-title":"Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin?","volume":"119","author":"Banaszkiewicz","year":"2012","journal-title":"J Neural Transm (Vienna)."},{"key":"10.1016\/j.jns.2018.09.022_bb0655","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.expneurol.2012.10.014","article-title":"Circadian and sleep disorder in Huntington's disease","volume":"243","author":"Morton","year":"2013","journal-title":"Exp Neurol."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0660","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.parkreldis.2010.02.009","article-title":"Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease","volume":"16","author":"Aziz","year":"2010","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.jns.2018.09.022_bb0665","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jns.2016.03.021","article-title":"Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function","volume":"364","author":"Baker","year":"2016","journal-title":"J Neurol Sci."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0670","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1550059416632413","article-title":"Wake and sleep EEG in patients with Huntington disease: An eLORETA study and review of the literature","volume":"48","author":"Piano","year":"2017","journal-title":"Clin EEG Neurosci."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0675","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: widespread pathology in Huntington's disease","volume":"8","author":"van der Burg","year":"2009","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0680","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ana.25007","article-title":"Body weight is a robust predictor of clinical progression in Huntington disease","volume":"82","author":"van der Burg","year":"2017","journal-title":"Ann Neurol."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0685","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","article-title":"Treating the whole body in Huntington's disease","volume":"14","author":"Carroll","year":"2015","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0690","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1468-1331.2010.02973.x","article-title":"Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease","volume":"17","author":"Aziz","year":"2010","journal-title":"Eur J Neurol."},{"issue":"1-2","key":"10.1016\/j.jns.2018.09.022_bb0695","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jns.2015.11.015","article-title":"Male sexual function in presymptomatic gene carriers and patients with Huntington's disease","volume":"359","author":"Kolenc","year":"2015","journal-title":"J Neurol Sci."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0700","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.nbd.2010.08.009","article-title":"Reduced gluconeogenesis and lactate clearance in Huntington's disease","volume":"40","author":"Josefsen","year":"2010","journal-title":"Neurobiol Dis."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0705","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbalip.2014.12.018","article-title":"The impairment of cholesterol metabolism in Huntington disease","volume":"1851","author":"Leoni","year":"2015","journal-title":"Biochim Biophys Acta."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0710","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/jnnp.2009.191833","article-title":"Systemic energy homeostasis in Huntington's disease patients","volume":"81","author":"Aziz","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb0715","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1212\/WNL.0b013e3181b04aa2","article-title":"Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants","volume":"73","author":"Marder","year":"2009","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0720","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JHD-150152","article-title":"Abnormal weight and body mass index in children with Juvenile Huntington's sisease","volume":"4","author":"Tereshchenko","year":"2015","journal-title":"J Huntingtons Dis."},{"issue":"15","key":"10.1016\/j.jns.2018.09.022_bb0725","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/mds.23337","article-title":"Challenges assessing clinical endpoints in early Huntington disease","volume":"25","author":"Paulsen","year":"2010","journal-title":"Mov Disord."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb0730","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/mds.25101","article-title":"Clinical predictors of driving status in Huntington's disease","volume":"27","author":"Beglinger","year":"2012","journal-title":"Mov Disord."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0735","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jamda.2014.01.010","article-title":"Clinical, demographic, and pharmacologic features of nursing home residents with Huntington's disease","volume":"15","author":"Zarowitz","year":"2014","journal-title":"J Am Med Dir Assoc."},{"key":"10.1016\/j.jns.2018.09.022_bb0740","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gaitpost.2016.07.014","article-title":"Motor-cognitive dual-task deficits in individuals with early-mid stage Huntington disease","volume":"49","author":"Fritz","year":"2016","journal-title":"Gait & posture."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0745","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/mds.24908","article-title":"Huntington's disease: objective assessment of posture--a link between motor and functional deficits","volume":"27","author":"Reilmann","year":"2012","journal-title":"Mov Disord."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0750","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.gaitpost.2012.05.028","article-title":"Analysis of gait and balance through a single triaxial accelerometer in presymptomatic and symptomatic Huntington's disease","volume":"37","author":"Dalton","year":"2013","journal-title":"Gait & posture."},{"issue":"1-2","key":"10.1016\/j.jns.2018.09.022_bb0755","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jns.2010.08.002","article-title":"Deficits in stepping response time are associated with impairments in balance and mobility in people with Huntington disease","volume":"298","author":"Goldberg","year":"2010","journal-title":"J Neurol Sci."},{"issue":"14","key":"10.1016\/j.jns.2018.09.022_bb0760","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/mds.23309","article-title":"Impaired postural stability as a marker of premanifest Huntington's disease","volume":"25","author":"Salomonczyk","year":"2010","journal-title":"Mov Disord."},{"issue":"7","key":"10.1016\/j.jns.2018.09.022_bb0765","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mds.22003","article-title":"Falls and gait disturbances in Huntington's disease","volume":"23","author":"Grimbergen","year":"2008","journal-title":"Mov Disord."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0770","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0269215513487235","article-title":"Video game play (Dance Dance Revolution) as a potential exercise therapy in Huntington's disease: a controlled clinical trial","volume":"27","author":"Kloos","year":"2013","journal-title":"Clin Rehabil."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0775","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00415-016-8310-1","article-title":"Exercise effects in Huntington disease","volume":"264","author":"Frese","year":"2017","journal-title":"J Neurol."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb0780","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.clineuro.2013.10.002","article-title":"Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI: a randomized controlled longitudinal trial","volume":"115","author":"Pickut","year":"2013","journal-title":"Clin Neurol Neurosurg."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0785","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/nmt.14.58","article-title":"Cognitive interventions to enhance neural compensation in Huntington's disease","volume":"5","author":"Andrews","year":"2015","journal-title":"Neurodegener Dis Manag."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0790","first-page":"1382","article-title":"Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease","volume":"70","author":"Marder","year":"2013","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0795","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/mds.27239","article-title":"Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease","volume":"33","author":"Tanner","year":"2018","journal-title":"Mov Disord."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0800","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0805","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0810","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ptj\/pzx031","article-title":"Physical activity self-management and coaching compared to social interaction in Huntington disease: Results From the ENGAGE-HD randomized, controlled, pilot feasibility trial","volume":"97","author":"Busse","year":"2017","journal-title":"Phys Ther."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0815","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3233\/JHD-160192","article-title":"Health care delivery practices in Huntington's disease specialty clinics: An international survey","volume":"5","author":"Frich","year":"2016","journal-title":"J Huntingtons Dis."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0820","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"American Academy of N. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0825","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","article-title":"Earliest functional declines in Huntington disease","volume":"178","author":"Beglinger","year":"2010","journal-title":"Psychiatry Res."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0830","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington's disease: clinical correlates of disability and progression","volume":"61","author":"Mahant","year":"2003","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0835","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","article-title":"Treatment options for chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert Rev Neurother."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0840","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0845","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine","volume":"24","author":"Brusa","year":"2009","journal-title":"Mov Disord."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0850","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004850-200203000-00009","article-title":"High-dose olanzapine in Huntington's disease","volume":"17","author":"Bonelli","year":"2002","journal-title":"Int Clin Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0855","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology."},{"issue":"18","key":"10.1016\/j.jns.2018.09.022_bb0860","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opin Pharmacother."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0865","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","article-title":"Chorea associated with Huntington's disease: to treat or not to treat?","volume":"29","author":"Jankovic","year":"2014","journal-title":"Mov Disord."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0870","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","author":"Schultz","year":"2018","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0875","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial","volume":"316","author":"Huntington Study Group","year":"2016","journal-title":"JAMA."},{"issue":"8","key":"10.1016\/j.jns.2018.09.022_bb0880","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov Disord."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0885","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","article-title":"Analysis of CYP2D6 genotype and response to tetrabenazine","volume":"28","author":"Mehanna","year":"2013","journal-title":"Mov Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0890","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2011.10.021","article-title":"An evidence-based approach in the treatment of Huntington's disease","volume":"18","author":"Mestre","year":"2012","journal-title":"Parkinsonism Relat Disord."},{"issue":"7","key":"10.1016\/j.jns.2018.09.022_bb0895","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A andomized trial of amantadine in Huntington disease","volume":"60","author":"O'Suilleabhain","year":"2003","journal-title":"Arch Neurol."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0900","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","author":"Huntington Study Group","year":"2003","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb0905","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol."},{"key":"10.1016\/j.jns.2018.09.022_bb0910","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","volume":"3","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb0915","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.gaitpost.2014.07.018","article-title":"Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, Activities-specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease","volume":"40","author":"Kloos","year":"2014","journal-title":"Gait Posture"},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0920","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-1331.2012.03760.x","article-title":"Physical therapy in Huntington's disease--toward objective assessments?","volume":"20","author":"Bohlen","year":"2013","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.jns.2018.09.022_bb0925","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2017.02.054","article-title":"Quantitative biomechanical assessment of trunk control in Huntington's disease reveals more impairment in static than dynamic tasks","volume":"376","author":"Kegelmeyer","year":"2017","journal-title":"J Neurol Sci."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb0930","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/mds.25578","article-title":"Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease","volume":"28","author":"Gluhm","year":"2013","journal-title":"Mov Disord."},{"issue":"7","key":"10.1016\/j.jns.2018.09.022_bb0935","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/jnnp-2011-301940","article-title":"Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease","volume":"83","author":"Stout","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0940","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S2215-0366(16)30144-4","article-title":"Changes in mental state and behaviour in Huntington's disease","volume":"3","author":"Eddy","year":"2016","journal-title":"Lancet Psychiatry."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb0945","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/mds.25980","article-title":"Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease","volume":"29","author":"Moulton","year":"2014","journal-title":"Mov Disord."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb0950","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1517\/14656566.2014.918955","article-title":"Treating psychosis in movement disorder patients: a review","volume":"15","author":"Borek","year":"2014","journal-title":"Expert Opin Pharmacother."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0955","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-140109","article-title":"Unawareness of deficits in Huntington's disease","volume":"3","author":"Sitek","year":"2014","journal-title":"J Huntingtons Dis."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0960","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","article-title":"Longitudinal psychiatric symptoms in prodromal Huntington's disease: A decade of data","volume":"173","author":"Epping","year":"2016","journal-title":"Am J Psychiatry."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0965","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mds.22837","article-title":"Validation of self-report depression rating scales in Huntington's disease","volume":"25","author":"De Souza","year":"2010","journal-title":"Mov Disord."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0970","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.genhosppsych.2013.01.015","article-title":"Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy","volume":"35","author":"Cusin","year":"2013","journal-title":"Gen Hosp Psychiatry."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0975","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1176\/appi.neuropsych.15040084","article-title":"Differential response to ECT of psychotic and affective symptoms in Huntington's disease: A case report","volume":"28","author":"Petit","year":"2016","journal-title":"J Neuropsych Clin Neurosci"},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb0980","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.pjnns.2014.10.006","article-title":"Huntington Disease - principles and practice of nutritional management","volume":"48","author":"Zukiewicz-Sobczak","year":"2014","journal-title":"Neurol Neurochir Pol."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0985","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JHD-150176","article-title":"Long-term use of modified diets in Huntington's disease: A descriptive clinical practice analysis on improving dietary enjoyment","volume":"5","author":"Moorhouse","year":"2016","journal-title":"J Huntingtons Dis."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb0990","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.anl.2003.11.001","article-title":"Oropharyngeal dysphagia in a case of Huntington's disease","volume":"31","author":"Hamakawa","year":"2004","journal-title":"Auris Nasus Larynx."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb0995","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JHD-160229","article-title":"The effect of music therapy in patients with Huntington's disease: A randomized controlled trial","volume":"6","author":"van Bruggen-Rufi","year":"2017","journal-title":"J Huntingtons Dis."},{"key":"10.1016\/j.jns.2018.09.022_bb1000","series-title":"Palliative Care in Huntington Disease: Personal Reflections and a Review of the Literature, Tremor and Other Hyperkinetic Movements","first-page":"454","volume":"7","author":"Tarolli","year":"2017"},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb1005","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s11136-016-1354-y","article-title":"New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system)","volume":"25","author":"Carlozzi","year":"2016","journal-title":"Qual Life Res."},{"issue":"7","key":"10.1016\/j.jns.2018.09.022_bb1010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/mds.27363","article-title":"Huntington's disease: Current and future therapeutic prospects","volume":"33","author":"Kieburtz","year":"2018","journal-title":"Mov Disord."},{"issue":"12","key":"10.1016\/j.jns.2018.09.022_bb1015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb1020","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease","volume":"28","author":"Huntington Study Group Hart Investigators","year":"2013","journal-title":"Mov Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb1025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/13543784.2016.1153627","article-title":"Pridopidine for the treatment of Huntington's disease","volume":"25","author":"Shannon","year":"2016","journal-title":"Expert Opin Investig Drugs."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb1030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","article-title":"Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"14","author":"Huntington Study Group Reach2HD Investigators","year":"2015","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb1035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173872","article-title":"Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial","volume":"12","author":"Gelderblom","year":"2017","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb1040","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci6030038","article-title":"Deep brain stimulation in Huntington's disease-preliminary evidence on pathophysiology, efficacy and safety","volume":"6","author":"Wojtecki","year":"2016","journal-title":"Brain Sci."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb1045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2013.11.007","article-title":"A 5-year follow-up of deep brain stimulation in Huntington's disease","volume":"20","author":"Lopez-Sendon Moreno","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb1050","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00429-014-0805-x","article-title":"Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease","volume":"220","author":"Beste","year":"2015","journal-title":"Brain Struct Funct."},{"key":"10.1016\/j.jns.2018.09.022_bb1055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fnsys.2015.00032","article-title":"Preserving cortico-striatal function: deep brain stimulation in Huntington's disease","volume":"9","author":"Nagel","year":"2015","journal-title":"Front Syst Neurosci."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb1060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.09.022_bb1065","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: From current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am J Med Genet A."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb1070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","article-title":"Triheptanoin improves brain energy metabolism in patients with Huntington disease","volume":"84","author":"Adanyeguh","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2018.09.022_bb1075","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/bs.pbr.2016.12.011","article-title":"From open to large-scale randomized cell transplantation trials in Huntington's disease: Lessons from the multicentric intracerebral grafting in Huntington's disease trial (MIG-HD) and previous pilot studies","volume":"230","author":"Bachoud-Levi","year":"2017","journal-title":"Prog Brain Res."},{"issue":"11","key":"10.1016\/j.jns.2018.09.022_bb1080","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.jns.2018.09.022_bb1085","doi-asserted-by":"crossref","DOI":"10.1038\/srep31652","article-title":"Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease","volume":"6","author":"Garcia-Miralles","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.jns.2018.09.022_bb1090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol Dis."},{"issue":"6","key":"10.1016\/j.jns.2018.09.022_bb1095","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.27010","article-title":"A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease","volume":"32","author":"Verny","year":"2017","journal-title":"Mov Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.09.022_bb1100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2016.12","article-title":"Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington's disease mouse models","volume":"24","author":"Pollock","year":"2016","journal-title":"Mol Ther."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb1105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11910-017-0711-8","article-title":"Linking pathogenesis to the development of experimental therapeutics","volume":"17","author":"Mestre","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"10.1016\/j.jns.2018.09.022_bb1110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.omtm.2017.05.001","article-title":"Preclinical evaluation of a lentiviral vector for huntingtin silencing","volume":"5","author":"Cambon","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"2","key":"10.1016\/j.jns.2018.09.022_bb1115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat Genet."},{"issue":"20","key":"10.1016\/j.jns.2018.09.022_bb1120","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1016\/j.jns.2018.09.022_bb1125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant Huntingtin Allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol Ther."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb1130","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem Cell Reports."},{"issue":"9","key":"10.1016\/j.jns.2018.09.022_bb1135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107434","article-title":"Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients","volume":"9","author":"Skotte","year":"2014","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.jns.2018.09.022_bb1140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mds.25835","article-title":"Prospects for neuroprotective therapies in prodromal Huntington's disease","volume":"29","author":"Chandra","year":"2014","journal-title":"Mov Disord."},{"issue":"10","key":"10.1016\/j.jns.2018.09.022_bb1145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","article-title":"PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease","volume":"82","author":"Rosas","year":"2014","journal-title":"Neurology."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18303848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18303848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:45:14Z","timestamp":1758383114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18303848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":229,"alternative-id":["S0022510X18303848"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.09.022","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Huntington disease: A quarter century of progress since the gene discovery","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}